Innoviva (INVA) Shareholder's Equity Growth (5y) (2014 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.00% |
| Dec 31, 2025 | 14.05% |
| Sep 30, 2025 | 13.56% |
| Jun 30, 2025 | 7.72% |
| Mar 31, 2025 | 9.77% |
| Dec 31, 2024 | 15.10% |
| Sep 30, 2024 | 18.70% |
| Jun 30, 2024 | 21.95% |
| Mar 31, 2024 | 28.62% |
| Dec 31, 2023 | 33.52% |
| Sep 30, 2023 | 50.79% |
| Jun 30, 2023 | 41.00% |
| Mar 31, 2023 | 35.92% |
| Dec 31, 2022 | 34.07% |
| Sep 30, 2022 | 37.29% |
| Jun 30, 2022 | 31.32% |
| Mar 31, 2022 | 29.57% |
| Dec 31, 2021 | 28.40% |
| Sep 30, 2021 | 27.25% |
| Jun 30, 2021 | 25.27% |
| Mar 31, 2021 | 31.45% |
| Dec 31, 2020 | 30.42% |
| Sep 30, 2020 | 29.60% |
| Jun 30, 2020 | 29.74% |
| Mar 31, 2020 | 28.91% |
| Dec 31, 2019 | 28.71% |
| Sep 30, 2019 | 28.25% |
| Jun 30, 2019 | 27.09% |
| Mar 31, 2019 | -5.35% |
| Dec 31, 2018 | -11.87% |
| Sep 30, 2018 | -18.41% |
| Jun 30, 2018 | -30.70% |
| Mar 31, 2018 | -34.03% |
| Dec 31, 2017 | -28.95% |
| Sep 30, 2017 | -26.87% |
| Jun 30, 2017 | -28.97% |
| Mar 31, 2017 | -124.09% |
| Dec 31, 2016 | -32.31% |
| Sep 30, 2016 | -44.13% |
| Jun 30, 2016 | -57.49% |
| Dec 31, 2015 | -72.52% |
| Dec 31, 2014 | -3.40% |